Actively Recruiting
A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Stroke
Led by Tianjin Huanhu Hospital · Updated on 2024-10-29
6000
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Stroke is the second leading cause of death worldwide, killing nearly 7 million people every year. Acute ischemic stroke is caused by focal cerebral hypoperfusion, usually due to embolism or atherosclerotic disease . Ischemic strokes account for 60-70% of all strokes worldwide and are severely debilitating, drawing considerable attention due to their high prevalence.The majority of studies comparing the efficacy and safety of teneplase and alteplase are predominantly randomized controlled trials with limited representation from real-world studies.The aim of this study is to compare the safety, efficacy and economic benefits of recombinant human TNK tissue plasminogen activator (tenecteplase, rhTNK-tPA, TNK) and recombinant tissue plasminogen activator (alteplase, rtPA) in clinical practice. This study aimed to establish a foundation for refining intravenous thrombolytic therapy tailored to various patient profiles and to guide clinicians in selecting the most suitable thrombolytic treatment options.
CONDITIONS
Official Title
A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Symptoms of neurological deficit caused by ischemic stroke
- Time from stroke symptom onset to treatment is 4.5 hours or less
- Age 18 years or older
- Signed informed consent by patient or legally authorized representative
You will not qualify if you...
- Any absolute contraindication to thrombolysis as per Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023
- Allergy to tenecteplase or alteplase
- Participation in another clinical trial within the previous 3 months
- Other conditions deemed inappropriate for participation in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Huanhu Hospital
Tianjin, Tianjin Municipality, China, 300350
Actively Recruiting
Research Team
S
Shoufeng Liu, MD
CONTACT
Y
Yalin Guan, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here